PierianDx has raised a little more than USD 3 million in new investment from unspecified sources, according to a filingwith the US Securities and Exchange Commission. The total planned size of the offering is USD 5 million in equity and options, the St. Louis-based company disclosed this week.

PierianDx, which spun out of Washington University in 2014, offers a WUSTL-developed software tool called Clinical Genomicist Workstation to help clinical laboratories manage next-generation sequencing data. Since last fall, the software also has supported clinical microarray technology.

The company also provides cloud hosting, a bioinformatics database, clinical interpretation, and related consulting services.

This is the first known new investment in PierianDx since a USD 9.25 million Series A round of venture capital announced in early 2016. Health Catalyst Capital Management led that round, with participation from the  Inova Translational Medicine Institute, ARUP Laboratories, and an affiliate of Ocean Road Advisors.

PierianDx, which has not disclosed its annual revenues, has made one acquisition, purchasing bioinformatics vendor Tute Genomics in September 2016. – Genome Web